Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Condition(s):Breast Ductal Carcinoma in SituLast Updated:August 6, 2019Recruiting
Hide Studies Not Open or Pending
Condition(s):Breast Ductal Carcinoma in SituLast Updated:August 6, 2019Recruiting
Condition(s):Intraductal Carcinoma and Lobular Carcinoma in SituLast Updated:August 25, 2016Completed
Condition(s):Breast Ductal Carcinoma In SituLast Updated:February 15, 2024Active, not recruiting
Condition(s):Breast CancerLast Updated:January 19, 2024Completed
Condition(s):Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast CancerLast Updated:July 21, 2015Completed
Condition(s):Ductal Breast Carcinoma in SituLast Updated:March 7, 2024Recruiting
Condition(s):Ductal Carcinoma in SituLast Updated:April 9, 2020Terminated
Condition(s):Breast CancerLast Updated:February 25, 2013Terminated
Condition(s):Breast CarcinomaLast Updated:May 22, 2014Terminated
Condition(s):Breast CancerLast Updated:December 4, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.